Published in Endocrinology on April 26, 2007
Hormonal modulation of endothelial NO production. Pflugers Arch (2010) 1.26
Lactation and maternal measures of subclinical cardiovascular disease. Obstet Gynecol (2010) 1.07
Levosimendan induces NO production through p38 MAPK, ERK and Akt in porcine coronary endothelial cells: role for mitochondrial K(ATP) channel. Br J Pharmacol (2009) 0.95
Lactation and maternal subclinical cardiovascular disease among premenopausal women. Am J Obstet Gynecol (2012) 0.90
Prolactin levels, endothelial dysfunction, and the risk of cardiovascular events and mortality in patients with CKD. Clin J Am Soc Nephrol (2011) 0.90
Plasma prolactin level and risk of incident hypertension in postmenopausal women. J Hypertens (2010) 0.87
Breast feeding increases vasoconstriction induced by electrical field stimulation in rat mesenteric artery. Role of neuronal nitric oxide and ATP. PLoS One (2013) 0.82
The prolactin family hormones regulate vascular tone through NO and prostacyclin production in isolated rat aortic rings. Acta Pharmacol Sin (2015) 0.81
Coronary Microvascular Function and Beyond: The Crosstalk between Hormones, Cytokines, and Neurotransmitters. Int J Endocrinol (2015) 0.80
Prolactin and its 16-kDa N-terminal fragment: are higher in patients with precapillary pulmonary hypertension than in a healthy control group. Tex Heart Inst J (2012) 0.77
Microcirculation and atherothrombotic parameters in prolactinoma patients: a pilot study. Pituitary (2012) 0.75
Genome-wide association of early-onset myocardial infarction with single nucleotide polymorphisms and copy number variants. Nat Genet (2009) 12.19
Biological, physiological, pathophysiological, and pharmacological aspects of ghrelin. Endocr Rev (2004) 3.79
Galectin-3-expression analysis in the surgical selection of follicular thyroid nodules with indeterminate fine-needle aspiration cytology: a prospective multicentre study. Lancet Oncol (2008) 2.32
Hypopituitarism. Lancet (2007) 2.27
Ghrelin and des-acyl ghrelin inhibit cell death in cardiomyocytes and endothelial cells through ERK1/2 and PI 3-kinase/AKT. J Cell Biol (2002) 1.97
Stent thrombosis with everolimus-eluting stents: meta-analysis of comparative randomized controlled trials. Circ Cardiovasc Interv (2012) 1.89
Influence of 9p21.3 genetic variants on clinical and angiographic outcomes in early-onset myocardial infarction. J Am Coll Cardiol (2011) 1.73
Relationship between central sympathetic drive and magnetic resonance imaging-determined left ventricular mass in essential hypertension. Circulation (2007) 1.69
Time course of sympathetic neural hyperactivity after uncomplicated acute myocardial infarction. Circulation (2002) 1.61
Hypothalamopituitary dysfunction following traumatic brain injury and aneurysmal subarachnoid hemorrhage: a systematic review. JAMA (2007) 1.59
The cut-off limits of the GH response to GH-releasing hormone-arginine test related to body mass index. Eur J Endocrinol (2005) 1.59
Copeptin (CTproAVP), a new tool for understanding the role of vasopressin in pathophysiology. Clin Chem Lab Med (2014) 1.49
Gender differences in sympathetic neural activation following uncomplicated acute myocardial infarction. Eur Heart J (2009) 1.48
Endocrine function is altered in chronic migraine patients with medication-overuse. Headache (2006) 1.47
A randomized, controlled, multicenter trial to evaluate the safety and efficacy of zotarolimus- versus paclitaxel-eluting stents in de novo occlusive lesions in coronary arteries The ZoMaxx I trial. JACC Cardiovasc Interv (2008) 1.47
Immunosuppressive Therapy for the Prevention of Restenosis after Coronary Artery Stent Implantation (IMPRESS Study). J Am Coll Cardiol (2002) 1.46
Impact of prosthetic mitral rings on aortomitral apparatus function: a cardiac magnetic resonance imaging study. Ann Thorac Surg (2009) 1.45
Expression of ghrelin and of the GH secretagogue receptor by pancreatic islet cells and related endocrine tumors. J Clin Endocrinol Metab (2002) 1.45
Late and very late coronary stent thrombosis: Intravascular ultrasound findings and associations with antiplatelet therapy. Catheter Cardiovasc Interv (2013) 1.42
Sympathetic neural activation in nondiabetic metabolic syndrome and its further augmentation by hypertension. Hypertension (2004) 1.42
Implications of new ESC/EACTS guidelines on myocardial revascularisation for patients with multi-vessel coronary artery disease. Eur J Cardiothorac Surg (2011) 1.41
Numbers needed to treat (lives!) and numbers needed to save (money). EuroIntervention (2013) 1.41
The sympathetic drive after acute myocardial infarction in hypertensive patients. Am J Hypertens (2006) 1.41
On the current epidemic outburst of meta-analytic rage in interventional cardiology. EuroIntervention (2009) 1.40
Ghrelin stimulates, whereas des-octanoyl ghrelin inhibits, glucose output by primary hepatocytes. J Clin Endocrinol Metab (2004) 1.39
Sympathetic activation and vasoregulation in response to carbohydrate ingestion in patients with congestive heart failure. Can J Cardiol (2012) 1.39
Delayed postpartum hemorrhage: the implications of making a diagnostic mistake. Arch Gynecol Obstet (2012) 1.38
Dual effects of IGFBP-3 on endothelial cell apoptosis and survival: involvement of the sphingolipid signaling pathways. FASEB J (2004) 1.32
Residual pituitary function after brain injury-induced hypopituitarism: a prospective 12-month study. J Clin Endocrinol Metab (2005) 1.32
Extracellular vesicles as an emerging mechanism of cell-to-cell communication. Endocrine (2012) 1.32
p130Cas interacts with estrogen receptor alpha and modulates non-genomic estrogen signaling in breast cancer cells. J Cell Sci (2004) 1.29
Traumatic brain injury and subarachnoid haemorrhage are conditions at high risk for hypopituitarism: screening study at 3 months after the brain injury. Clin Endocrinol (Oxf) (2004) 1.29
Growth hormone-releasing hormone promotes survival of cardiac myocytes in vitro and protects against ischaemia-reperfusion injury in rat heart. Cardiovasc Res (2009) 1.26
Levosimendan: molecular mechanisms and clinical implications: consensus of experts on the mechanisms of action of levosimendan. Int J Cardiol (2011) 1.24
Neuroendocrine and peripheral activities of ghrelin: implications in metabolism and obesity. Eur J Pharmacol (2002) 1.24
Long-term safety of pegvisomant in patients with acromegaly: comprehensive review of 1288 subjects in ACROSTUDY. J Clin Endocrinol Metab (2012) 1.24
Relationship between central sympathetic activity and stages of human hypertension. Am J Hypertens (2004) 1.22
Obestatin promotes survival of pancreatic beta-cells and human islets and induces expression of genes involved in the regulation of beta-cell mass and function. Diabetes (2007) 1.22
Gender-related differences in the sympathetic vasoconstrictor drive of normal subjects. Clin Sci (Lond) (2007) 1.21
Levetiracetam for cerebellar tremor in multiple sclerosis: an open-label pilot tolerability and efficacy study. J Neurol (2006) 1.20
Stimulation of voluntary ethanol intake by cannabinoid receptor agonists in ethanol-preferring sP rats. Psychopharmacology (Berl) (2001) 1.20
Ghrelin and des-acyl ghrelin promote differentiation and fusion of C2C12 skeletal muscle cells. Mol Biol Cell (2007) 1.19
Impact of type 2 diabetes mellitus on sympathetic neural mechanisms in hypertension. Circulation (2003) 1.18
1α,25-dihydroxycholecalciferol induces nitric oxide production in cultured endothelial cells. Cell Physiol Biochem (2011) 1.18
Interaction between inflammation and angiogenesis during different stages of cervical carcinogenesis. Gynecol Oncol (2007) 1.18
Baclofen suppresses motivation to consume alcohol in rats. Psychopharmacology (Berl) (2003) 1.14
The endocrine response to ghrelin as a function of gender in humans in young and elderly subjects. J Clin Endocrinol Metab (2003) 1.12
Endocannabinoid system and alcohol addiction: pharmacological studies. Pharmacol Biochem Behav (2005) 1.09
Atorvastatin combined to interferon to verify the efficacy (ACTIVE) in relapsing-remitting active multiple sclerosis patients: a longitudinal controlled trial of combination therapy. Mult Scler (2010) 1.09
Unraveling the role of the ghrelin gene peptides in the endocrine pancreas. J Mol Endocrinol (2010) 1.09
Arsenic trioxide and breast cancer: analysis of the apoptotic, differentiative and immunomodulatory effects. Breast Cancer Res Treat (2002) 1.07
Unacylated ghrelin acts as a potent insulin secretagogue in glucose-stimulated conditions. Am J Physiol Endocrinol Metab (2007) 1.06
Differential expression of microRNAs between eutopic and ectopic endometrium in ovarian endometriosis. J Biomed Biotechnol (2010) 1.06
Stent Type and Risk of Late Cerebral Events After Carotid Artery Stenting. J Am Coll Cardiol (2015) 1.05
Expression of ghrelin and biological activity of specific receptors for ghrelin and des-acyl ghrelin in human prostate neoplasms and related cell lines. Eur J Endocrinol (2004) 1.05
Effect of food restriction on ghrelin in normal-cycling female rats and in pregnancy. Obes Res (2002) 1.04
Relationship of neurovascular compression to central sympathetic discharge and essential hypertension. J Am Coll Cardiol (2004) 1.03
Metabolic and endocrine effects of physiological increments in plasma ghrelin concentrations. Nutr Metab Cardiovasc Dis (2005) 1.03
Suppression by baclofen of alcohol deprivation effect in Sardinian alcohol-preferring (sP) rats. Drug Alcohol Depend (2003) 1.02
Baclofen-induced reduction of alcohol reinforcement in alcohol-preferring rats. Alcohol (2005) 1.02
Cardiovascular actions of the ghrelin gene-derived peptides and growth hormone-releasing hormone. Exp Biol Med (Maywood) (2011) 1.02
The IGF system. Acta Diabetol (2010) 1.01
Ghrelin and des-acyl ghrelin both inhibit isoproterenol-induced lipolysis in rat adipocytes via a non-type 1a growth hormone secretagogue receptor. Eur J Pharmacol (2004) 1.01
Neuroendocrine alterations in obese patients with sleep apnea syndrome. Int J Endocrinol (2010) 1.01
Obstructive sleep apnoea syndrome impairs insulin sensitivity independently of anthropometric variables. Clin Endocrinol (Oxf) (2003) 1.01
The GABA(B) receptor agonists baclofen and CGP 44532 prevent acquisition of alcohol drinking behaviour in alcohol-preferring rats. Alcohol Alcohol (2002) 1.01
Effects of acute administration of acylated and unacylated ghrelin on glucose and insulin concentrations in morbidly obese subjects without overt diabetes. Eur J Endocrinol (2009) 1.00
Suppressing effect of the cannabinoid CB1 receptor antagonist, SR147778, on alcohol intake and motivational properties of alcohol in alcohol-preferring sP rats. Alcohol Alcohol (2004) 1.00
Drug-eluting stent safety: findings from preclinical studies. Expert Rev Cardiovasc Ther (2008) 1.00
Acylated and unacylated ghrelin impair skeletal muscle atrophy in mice. J Clin Invest (2013) 0.99
Unacylated ghrelin is active on the INS-1E rat insulinoma cell line independently of the growth hormone secretagogue receptor type 1a and the corticotropin releasing factor 2 receptor. Mol Cell Endocrinol (2006) 0.99
Cardiac effects of ghrelin and its endogenous derivatives des-octanoyl ghrelin and des-Gln14-ghrelin. Eur J Pharmacol (2003) 0.98
Alprazolam (a benzodiazepine activating GABA receptor) reduces the neuroendocrine responses to insulin-induced hypoglycaemia in humans. Clin Endocrinol (Oxf) (2003) 0.97
Interobserver variability of colposcopic interpretations and consistency with final histologic results. J Low Genit Tract Dis (2004) 0.96
Proliferative and protective effects of growth hormone secretagogues on adult rat hippocampal progenitor cells. Endocrinology (2008) 0.96
Endocrine and metabolic responses to extreme altitude and physical exercise in climbers. Eur J Endocrinol (2007) 0.95
Unacylated ghrelin rescues endothelial progenitor cell function in individuals with type 2 diabetes. Diabetes (2010) 0.95
Trigeminal stimulation elicits a peripheral vestibular imbalance in migraine patients. Headache (2005) 0.95
Ghrelin secretion in childhood is refractory to the inhibitory effect of feeding. J Clin Endocrinol Metab (2004) 0.95
Chronic cerebrospinal venous insufficiency in multiple sclerosis: a highly prevalent age-dependent phenomenon. BMC Neurol (2013) 0.94
Cut-off limits of the GH response to GHRH plus arginine test and IGF-I levels for the diagnosis of GH deficiency in late adolescents and young adults. Eur J Endocrinol (2007) 0.94
The magnitude of sympathetic hyperactivity in pregnancy-induced hypertension and preeclampsia. Am J Hypertens (2003) 0.94
Long-term follow-up in adrenal incidentalomas: an Italian multicenter study. J Clin Endocrinol Metab (2014) 0.94
The antiproliferative effect of synthetic peptidyl GH secretagogues in human CALU-1 lung carcinoma cells. Endocrinology (2002) 0.93
Metabolic and cardiovascular outcomes in patients with Cushing's syndrome of different aetiologies during active disease and 1 year after remission. Clin Endocrinol (Oxf) (2011) 0.93
Heterogeneity of ghrelin/growth hormone secretagogue receptors. Toward the understanding of the molecular identity of novel ghrelin/GHS receptors. Neuroendocrinology (2007) 0.92
Differences in ethanol-induced conditioned taste aversion in Sardinian alcohol-preferring and Sardinian alcohol-nonpreferring rats. Alcohol (2002) 0.92
Ghrelin secretion is inhibited by glucose load and insulin-induced hypoglycaemia but unaffected by glucagon and arginine in humans. Clin Endocrinol (Oxf) (2004) 0.92
High-dose intramuscular octreotide in patients with acromegaly inadequately controlled on conventional somatostatin analogue therapy: a randomised controlled trial. Eur J Endocrinol (2009) 0.91
Levosimendan protection against kidney ischemia/reperfusion injuries in anesthetized pigs. J Pharmacol Exp Ther (2012) 0.91
Obestatin regulates adipocyte function and protects against diet-induced insulin resistance and inflammation. FASEB J (2012) 0.91
Suppressing effect of the cannabinoid CB1 receptor antagonist, SR 141716, on alcohol's motivational properties in alcohol-preferring rats. Eur J Pharmacol (2004) 0.90